Kenvue stock edges higher as Kimberly-Clark profit beat puts takeover vote back in play
27 January 2026
1 min read

Kenvue stock edges higher as Kimberly-Clark profit beat puts takeover vote back in play

New York, Jan 27, 2026, 10:52 EST — Regular session

Shares of Kenvue Inc (KVUE) edged up 0.2% to $17.68 in early Tuesday trading, following a quarterly profit beat from potential acquirer Kimberly-Clark (KMB). Kimberly-Clark also reaffirmed its focus on expanding in consumer health. The company’s shares gained 0.7%, reaching $101.89. 1

The move is crucial given the tight timeline. Shareholders will vote on Kimberly-Clark’s $40 billion bid for Kenvue on Jan. 29, following ISS’s recommendation to back the deal earlier this month. 2

Kenvue shareholders will get $3.50 in cash plus 0.14625 Kimberly-Clark shares for each Kenvue share, the companies confirmed at the deal’s announcement. The transaction, subject to shareholder and regulatory sign-off, is slated to close in the second half of 2026. Kimberly-Clark has secured financing and plans to cover the cash portion with existing cash, new debt, and proceeds from its upcoming International Family Care and Professional business deal. 3

That situation has pushed Kenvue into merger arbitrage territory — investors snap up the target and sometimes hedge the acquirer, betting on the difference between the offer price and the trading price of the target. When that spread widens, it typically signals the market is factoring in higher risks of the deal faltering, shrinking, or falling through.

Kimberly-Clark CEO Mike Hsu described the Kenvue deal on Tuesday as “a powerful next step” in the company’s ongoing transformation, adding that integration planning is underway. The company also noted that funds from its IFP transaction are intended to support the acquisition. 4

Shareholder meetings are set for Thursday morning and will take place virtually. Voting instructions must be submitted before the session, according to a proxy filing. 5

Deal risk remains a factor. Kenvue has been hit with lawsuits and regulatory scrutiny over legacy products, sparking debate among investors about the impact of these liabilities on the merged entity — and if they might delay the timeline. 6

Thursday’s vote is the immediate focus for investors. Once that’s settled, the spotlight will turn to fresh updates on litigation, financing structure, and how quickly regulators are moving — the key factors that will determine if Kenvue stays in deal mode or reverts to trading on its core fundamentals.

Stock Market Today

Mastercard stock price: MA slips as Dow hits 50,000; jobs and CPI data next week

Mastercard stock price: MA slips as Dow hits 50,000; jobs and CPI data next week

7 February 2026
New York, Feb 7, 2026, 11:18 EST — Market closed. Mastercard Incorporated shares (MA.N) last traded down 0.6% at $548.74 on Friday, after moving between $539.90 and $556.65. The stock is about 4% below its 52-week high, according to market data. That small drop still matters because payments names like Mastercard often trade as a clean read on consumer and travel spending. Heading into the new week, the focus shifts back to U.S. growth and rate expectations, which can move the group even when company news is thin. Friday’s tape was not thin. The Dow surged 2.47% to end above
Costco stock price retakes $1,000 — what traders are watching before Monday

Costco stock price retakes $1,000 — what traders are watching before Monday

7 February 2026
Costco closed Friday up 1.2% at $1,001.16, regaining the $1,000 level as about 2.36 million shares changed hands. January net sales rose 9.3% to $21.33 billion, with comparable sales up 7.1% and online sales surging 34.4%. Wells Fargo raised its price target to $950, maintaining a neutral rating. The next earnings call is set for March 5.
Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

7 February 2026
Johnson & Johnson shares rose 0.9% to $239.99 Friday after a New Jersey appeals court disqualified Beasley Allen from state talc cases, citing improper coordination with a former J&J attorney. The ruling affects about 3,600 state lawsuits, while a related federal motion is pending. J&J also reported early 12-month pilot data for its investigational AFib device at a cardiology meeting.
CoreWeave stock jumps again as Nvidia doubles down with $2 billion buy — what’s next for CRWV
Previous Story

CoreWeave stock jumps again as Nvidia doubles down with $2 billion buy — what’s next for CRWV

AppLovin stock rises as Needham turns bullish on e-commerce ads — what investors watch next
Next Story

AppLovin stock rises as Needham turns bullish on e-commerce ads — what investors watch next

Go toTop